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To accelerate the logical drug design procedure, we created the program “NAGARA,” a plugin for PyMOL,
and applied it to the discovery of small compounds called medical chaperones (MCs) that stabilize the
cellular form of a prion protein (PrPC). In NAGARA, we constructed a single platform to unify the docking
simulation (DS), free energy calculation by molecular dynamics (MD) simulation, and interfragment
interaction energy (IFIE) calculation by quantum chemistry (QC) calculation. NAGARA also enables large-
scale parallel computing via a convenient graphical user interface. Here, we demonstrated its perfor-
mance and its broad applicability from drug discovery to lead optimization with full compatibility with
various experimental methods including Western blotting (WB) analysis, surface plasmon resonance
(SPR), and nuclear magnetic resonance (NMR) measurements. Combining DS and WB, we discovered
anti-prion activities for two compounds and tegobuvir (TGV), a non-nucleoside non-structural protein
NS5B polymerase inhibitor showing activity against hepatitis C virus genotype 1. Binding proﬁles pre-
dicted by MD and QC are consistent with those obtained by SPR and NMR. Free energy analyses showed
that these compounds stabilize the PrPC conformation by decreasing the conformational ﬂuctuation of
the PrPC. Because TGV has been already approved as a medicine, its extension to prion diseases is
straightforward. Finally, we evaluated the afﬁnities of the fragmented regions of TGV using QC and found
a clue for its further optimization. By repeating WB, MD, and QC recursively, we were able to obtain the
optimum lead structure.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Conformational diseases [1] are primarily caused by the mis-
folding of disease-related proteins. Although prion diseases [2] are
known to be caused by the conformational conversion of a prion
protein [3], conformational instabilities resulting in oligomer for-
mation are regarded as the major causes of other neurodegenera-
tive diseases [4] (e.g., Alzheimer’s disease [5], Parkinson’s disease
[6], and amyotrophic lateral sclerosis [7]), certain psychiatric dis-
eases (e.g., schizophrenia [8]), diabetes mellitus (i.e., type-II dia-
betes) [9], and several cancers involving p53 mutation [10].
Medical chaperones (MCs) [11,12] speciﬁcally bind to and sta-
bilize the native conformation of relevant proteins and prevent
abnormal aggregate formation. They inhibit aggregate formation
even if the proteins are intrinsically disordered [13]. MCs can be
computationally designed to stabilize the conformations of nativeDrug Discovery and Medical
ifu 501-1193, Japan.
Inc. This is an open access article uor disordered protein structures. The most convenient and efﬁcient
approach to address the complicated computational demands for
the logical design of MCs is to modify and unify existing programs
into a new programwith a comprehensive graphical user interface
(GUI).
Docking simulations (DS) and molecular dynamics (MD) simu-
lations can be implemented on numerous GUI tools that are
developed for this purpose [14e20]. However, these tools were
found to be only partially applicable to the previously described
general MC design. Hence, here, we unify docking simulation (DS),
molecular dynamics (MD) simulations, and quantum chemistry
(QC) calculations into a single simulation platform called
“NAGARA.” Using NAGARA, we can prepare input ﬁles on a local PC
and run large-scale calculations on remote high-performance
computers (HPCs) such as Linux cluster machines.
Here, we demonstrated the performance of NAGARA through
the discovery of novel anti-prion agents. We characterized their
binding modes and possible anti-prion mechanisms, discussed the
possibility of extending these agents to a medicine for prion dis-
eases, and further obtained useful information with respect to leadnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Coding of NAGARA
NAGARA is a plugin for PyMOL [21,22] and integrates three main
GUIs: 1) DS, a GUI for DSs and large-scale screening via AutoDock
Vina [23]; 2) MD, a GUI for obtaining the stable structure of pro-
teineligand complexes and the binding free energy in MD simu-
lations via the Amber package [24]; and 3) QC, a PAICS GUI for
optimizing the MC molecular structure by QC calculations [25]
(Fig. 1, Supplementary Figs). Further details are in Supplementary
Material.2.2. Preparation of target protein structure and ligand database,
and the docking simulation (DS)
We performed in silico large-scale screening of ligands using our
program. The target receptor was the 3D structure of mouse prion
protein (mPrP) (PDBID:1ag2 [26]) downloaded from PDB [27]. The
Asinex subset (~360,000) and KEGG DRUG (~7000 approved drugs)
subset of Ligand Box [28] were used for ligand screening. Further
details are in Supplementary Methods section.2.3. Molecular dynamics simulation
The structures of the proteineligand complexes were optimized
in MD simulations, and the free energies of binding were calcu-
lated. Here, we selected complexes with three effective compounds
after adding the missing hydrogen atoms, and the ligands were
attached to PrP. The AMBER12SB force ﬁeld was used for proteins,
and the general AMBER force ﬁeld was used for ligands. The binding
free energy was computed using the MMePBSA method [29] and
Python script MMPBSA.py [30]. Further details are in Supplemen-
tary Methods section.Fig. 1. Overview of NAGARA and Flow of calculation for the discovery of a medical
chaperone (MC). (a) NAGARA integrates a preparation procedure and three physical
models: NAGARA DS, NAGARA MD, and NAGARA QC. (b) In NAGARA, three physical
models can be arbitrarily combined to obtain the desired statistical ensemble. (c) In the2.4. Quantum chemistry calculation
Finally, the proteineligand interactions were examined via QC
calculations based on the FMO method [31]. We used the atomic
coordinates obtained via the earlier process for the FMO calcula-
tions in this study. The tegobuvir (TGV) was divided into two
fragments (Frag A and Frag B) using the 6-31G basis set [25] (see
Fig. 4a). Further details are in Supplementary Methods section.DS procedure, NAGARA creates a project folder on the local PC and the remote HPC
server; the structure of the receptor and the ligands database are prepared in this
folder. The job will automatically run on the remote HPC server. Experimental
screening including organic synthesis and bioassay was subsequently performed for
selected candidates. In the MD simulation, the initial structure of the receptor and the
effective ligands were prepared and the MD simulation was performed to obtain the
best binding mode, DDG, and DDS. In the QC procedure, the PAICS input ﬁle was
initially prepared using the optimized complex structure. QC fragment molecular
orbital (FMO) calculations were then performed, and the interaction between the re-
ceptor and ligand were analyzed in detail for further ligand optimization.2.5. Compounds and experimental screening
Compounds were purchased from ASINEX (NC), and Chem-
Scene, LLC (NJ). The anti-prion activity assay was performed using
Western blotting (WB), as described in our previous paper [32]. We
used an immortalized neuronal mouse cell line persistently infec-
ted with the human TSE agent (Fukuoka-1 strain) [33].2.6. Recombinant mPrP (90e231)
Mouse prion protein of amino acid residues 90e231 (mPrP
(90e231)) was expressed and puriﬁed using an Escherichia coli
expression system; this protein has been previously described [34].
Themolecular weight of the puriﬁedmPrP (90e231) was measured
by matrix-assisted laser desorption ionization time-of-ﬂight mass
spectrometry (Bruker Daltonics, Billerica, MA, USA).2.7. Surface plasmon resonance measurements
Interactions between prion proteins and compounds were
analyzed using a Biacore T200 system (GE Healthcare, Buck-
inghamshire, UK). Experimental details are in Supplementary
Methods section.
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1He15N heteronuclear single quantum coherence (HSQC)
spectra were measured at 25 C on a Bruker Avance600 spec-
trometer equipped with a CryoProbe (Bruker BioSpin, Rheinstetten,
Germany) and were processed using the TOPSPIN-NMR software
package (Bruker BioSpin, Rheinstetten, Germany) and the Sparky
program [35]. Resonance frequencies in the spectra were identiﬁed
using the chemical shifts lists for mPrP (90e232) [36]. The protein
structure was generated using PyMOL [21] [22]. Experimental de-
tails are in Supplementary Methods section.
3. Results and discussion
As shown in Fig. 1c, the computational ﬂow utilized here is
grouped into three categories: stage 1 (DS), stage 2 (MD), and stage
3 (QC). After stage 1 in Fig. 1c (DS), we purchased or synthesized
100 compounds and performed the experimental screen using WB.
Fig. 2abc shows the chemical structures of the selected compounds
B05, G03, and tegobuvir (TGV), which effectively suppressed the
PrPSc in GT þ FK cells; their anti-prion activities as represented by
PrPSc (%) relative to those of DMSO obtained by WB are shown in
Fig. 2d. The IC50 of the most effective compound, TGV, was esti-
mated to be 1.7 mM according to WB [34] (data not shown).
At stage 2 (MD) in Fig. 1c, we calculated DDG upon binding. We
constructed the initial complex structures for MD on the basis of DS
binding modes and started the free energy calculation after system
equilibration for each complex. The binding mode of TGV and mPrP
predicted by MD is shown in Fig. 2f; it involves the hot spot in a
prion protein [34]. The calculated energy parameters DDG and
TDDS are less than 5.0 and 19 kcal/mol, respectively, as listed in
Table 1. In Fig. 2e, the calculated DDG and DDS values for repre-
sentative compounds including those of less effective ones are
plotted as a function of PrPSc (%). The DDG tended to decrease with
decreasing PrPSc (%), suggesting that the free energy of the system
is efﬁciently decreased upon ligand binding, supporting the MC
hypothesis. The DDS, in particular, substantially decreased withFig. 2. Chemical structures and biological and computational characterization of the effect
poundsdB05, G03, and TGVdare shown. (d) Anti-prion efﬁciencies of the selected compou
GT þ FK cells in the presence of compounds. Concentration of each compound was 10 mM.
compounds. DDG and DDS decreased upon decrease in PrPSc (%), suggesting that an anti
conformational stabilization was associated with the decrease in the conformational ﬂuctudecreasing PrPSc (%), as shown in Fig. 2e, indicating that the stabi-
lization of the PrPC conformation is associated with the decrease in
the local ﬂuctuation around the binding sites. Thus MD simulation
offers a clue for understanding the anti-prion mechanism.
We subsequently measured the afﬁnity of the selected com-
pounds to mPrP by SPR. As shown in Fig. 3abc, the dissociation
constants (Kd) of B05, G03, and TGV were estimated to be 49, 24,
and 19 mM, respectively; these results are approximately consistent
with the PrPSc (%) (Fig. 2d). Although the SPR response was rela-
tively high in B05, this high response may be attributed to the non-
speciﬁc interaction of B05. Anti-prion activities were well corre-
lated with the binding constants rather than the size of overall
responses, suggesting that the speciﬁc interaction is the key to
suppressing the conversion reaction.
Moreover, we measured the chemical shift perturbation proﬁle
of a prion protein upon binding of the TGV. Fig. 3d shows the su-
perposition of the HSQC spectra of mPrP (90e231) with and
without TGV. Five peaks corresponding to H187, T188, T192, K194,
and G195 exhibited clear chemical shifts (Fig. 3d). The distribution
of the chemical shift perturbation is plotted as a function of residue
number in Fig. 3e and mapped on the 3D structure of a prion
protein in Fig. 3f. These experimentally determined binding sites
correspond well with those predicted by MD simulation (Fig. 2f).
At stage 3 (QC) in Fig. 1c, we evaluated the local interaction
energy by IFIE using the PAICS GUI. In the interaction analysis, we
selected amino acid residues located within 3.0 Å of TGV and
plotted their IFIE as a function of residue number, as shown in
Fig. 4b. These residues are located around the hot spots [34] of the
PrPC, which constitute the critical region of pathogenic conversion
to prions. The interaction energies between these selected residues
and both compounds were calculated at the HartreeeFock level.
Interestingly, TGV strongly interacts with R156, Q160, H187, and
K194, as shown in Fig. 4b.
For optimization of the lead compound, we divided TGV into
fragments A and B, as shown in the lower part of Fig. 4a. We then
evaluated the afﬁnity of each fragment by calculating its IFIE
independently, and we observed that fragment A has a higherive compounds. (a, b, c) The chemical structures of the ﬁnally selected effective com-
nds relative to the control (DMSO) represented by PrPSc (%) obtained by WB of PrPSc in
(e) DDG (:) and DDS (C) obtained by MD simulations for effective and non-effective
-prion activity was achieved by the stabilization of the PrPC conformation and that
ation. (f) Binding mode of TGV and mPrP complex after MD simulation.
Table 1
Calculated parameters and anti-PrPSc effects of compounds B05, G03, and TGV.
Compound no. DSa MD QC In vitro Ex vivo
Docking score DDS (e.u.)b DDG (kcal/mol)c IFIE (kcal/mol)d Kd (mM) PrPSc (%)e
B05 10.2 69.1 5.6 85.2 49.3 ± 1.0 49.9
G03 10.0 64.5 9.5 65.6 24.0 ± 2.8 45.9
TGV 9.9 79.6 8.1 88.2 19.2 ± 5.9 45.8
TGV(A) 52.0
TGV(B) 36.2
a The binding energy was obtained in the DS.
b The entropy calculated by MD simulation using the normal-mode entropy approximation.
c The binding free energy calculated by MD simulation using the normal-mode entropy approximation.
d The interaction energy between the compound and the whole PrP.
e The percentage of PrPSc after treatment by B05, G03, and TGV.
Fig. 3. Interaction analyses between compounds and mPrP (90e231) using SPR and NMR. SPR responses as a function of concentration of (a) B05, (b) G03, and (c) TGV were ﬁtted to
the theoretical binding isotherm under the assumption of a 1:1 binding model. KD ± S.D. (mM) and Rmax ± S.D. (r.u.) values for B05, G03, and TGV were estimated to be (49.3 ± 1.0,
320 ± 27), (24.0 ± 2.8, 66.1 ± 2.1), and (19.2 ± 5.9, 21.6 ± 1.7), respectively. (d) Overlay of the 1He15N HSQC spectra of mPrP (90e231) in the absence (black contours) and presence
(red contours) of TGV. (e) Chemical shift perturbations as a function of residue number. The 1H and 15N chemical shift changes were calculated using the function Dd ¼ [(Dd1H)
2 þ 0.17(Dd15N) 2]1/2. Secondary structural elements determined by NMR are shown by the bars at the top. (f) Mapping of the perturbed residues on the structure of mPrP (PDB entry
1AG2). Perturbed residues with Dd > 0.015 ppm are shown in red and those with 0.015 > Dd > 0.01 ppm are shown in orange.
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binds with the C-terminal of helix 2 (c.f. H187) and the loop region
between helices 1 and 2 (c.f. Q160), as shown in Fig. 4c, whereas
fragment B interacts with the loop regions between helices 2 and 3
(c.f. K194) and between S2 and helix 1 (c.f. R156), as shown in
Fig. 4d. Therefore, it may be advantageous to replace fragment B
with another fragment with higher afﬁnity. Thus, inter-fragment
interaction analysis of ligand fragments would be helpful to
obtain a clue for further optimization. In fact, we found numerous
derivatives of TGV with modiﬁcation of fragment B (data not
shown). Either by purchasing or synthesizing the derivatives, we
can conduct stage 2 in Fig. 1c. By repeatingWB, MD, and QC, we can
actually optimize the lead compound, i.e., TGV. However,
completing this process and ﬁnally obtaining the fully optimized
compounds is beyond the scope of this study.
TGV was initially developed as a novel imidazole inhibitor of
RNA replication of hepatitis C virus (HCV). Although TGV was
initially considered as a HCV NS5B polymerase inhibitor [37], it was
later demonstrated to not inhibit the NS5B enzymatic activity; an
alternative mechanism was subsequently proposed [38]. Althoughthe details of the working mechanism of TGV on HCV has not yet
been completely elucidated, in the case of its anti-prion effect, TGV
binds to the PrPC and stabilizes the PrPC conformation. Hence, TGV
is considered to be an MC [12].
Recently, various physiological functions of prion protein have
been observed, including immunoregulation, signal transduction,
copper binding, synaptic transmission, and induction of apoptosis
or protection against apoptotic stimuli [39]. Although the details of
these functions might be unknown, speciﬁc perturbation of prion
conformation would affect the immunoregulation process in rela-
tion to HCV infection. Alternatively, TGV might interact with some
unknown proteins that affect both the prion and HCV infection.
The hit rate of NAGARA in this study was on the order of several
percent, similar to that previously reported [32]. However, using
NAGARA, interaction analysis by MD promoted the lead selection
process by conﬁrming the action mechanism of the MC, i.e., by
suppressing the conformational ﬂuctuation of the target protein,
thereby inhibiting the mis-folding process. Furthermore, QC cal-
culations offered useful hints for further optimization. These as-
pects are strong advantages of NAGARA.
Fig. 4. Toward further optimization of TGV. (a) (Lower panel) Fragmentation of TGV into two parts: A and B. (Upper panel) Inter-fragment interaction energy (IFIE) corresponding to
each fragment. (b) IFIE for whole TGV and mPrP. (c) IFIE for fragment A and mPrP; fragment A speciﬁcally interacts with Q160 and H187. (d) IFIE for fragment B and mPrP; fragment
B speciﬁcally interacts with R156 and K194.
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procedure as follows: 1) structural determination of the target
protein, 2) in silico design of theMC’s chemical structure, 3) organic
synthesis of the MC, and 4) effectiveness testing by bioassay. Steps
1, 2, 3, and 4 conﬁrm the “localizability” of the hot spot [34],
“regulability” of the conformation, “synthesizability” of the
computationally designed MC structure, and “speciﬁcity” of its
biological function [11], respectively. Localizability can be esti-
mated by careful examination of the folding process or conforma-
tional ﬂuctuation at atomic resolution, whereas the regulability by
an MC can be evaluated, for instance, by computing the changes in
the stability (DDG) of the conformation upon MC binding to the
target protein using MD simulations and IFIE using QC calculations.
In contrast, synthesizability and speciﬁcity can be only proved by
empirical methods (organic synthesis and bioassay experiments,
respectively). In this regard, NAGARA is an indispensable measure
for step 2.
In summary, using NAGARA, we performed database screening
by DS and experimental screening, interaction analysis for further
lead selection using MD, and lead optimization by QC. By repeating
this procedure recursively, we were able to identify the most
effective drug candidate.
NAGARA can also be applied to the more general allosteric
regulation of proteins. An MC can be designed to bind within the
pocket of the protein (which is not necessarily an active site),
inducing an allosteric effect on the protein’s function.
4. Conclusion
We developed a plugin program, NAGARA, as a logical drug
design platform for MCs. NAGARA integrates DS for ligand database
searching, MD simulations for obtaining DDG upon binding of
candidate compounds, and QC calculations for further optimiza-
tion. Such integration is achieved by exploiting large-scale parallelcomputing with GUIs based on PyMOL. Here, we successfully
applied NAGARA to the discovery of MCs targeting prion diseases
and demonstrated its performance by identifying several novel
anti-prion compounds including TGV. TGV could be used in clinical
trials as it has already been approved as a medicine targeting HCV
infection. Moreover, NAGARA enables further optimization of TGV
with respect of anti-prion activity.
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